JG
PNT

Joel Greenblatt’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Joel Greenblatt’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,484
Closed -$140K – 1426
2023
Q2 		$140K Buy
+15,484
New +$137K ﹤0.01% 1256

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joel Greenblatt's PNT Position: Q3 2023 in Review

Joel Greenblatt sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 15,484 shares — an estimated $140K sold.

Joel Greenblatt first reported a position in PNT in Q2 2023 and held it in 1 quarter. The position peaked at $140K in Q2 2023. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Joel Greenblatt reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Joel Greenblatt sold 15,484 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $140K.
  • Joel Greenblatt first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Joel Greenblatt's POINT Biopharma Global Inc. Common Stock position peaked at $140K in Q2 2023.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on Gotham Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.